Molecular and Chemical Neuropathology

, Volume 10, Issue 3, pp 171–183 | Cite as

Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse

  • Richard E. Heikkila
  • Beth-Anne Sieber
  • Lawrence Manzino
  • Patricia K. Sonsalla
Original Articles


The discovery that a rather simple chemical substance can produce such a highly selective neuronal degeneration in the substantia nigra, the brain area most affected in Parkinson’s disease, has resulted in a vast amount of research with MPTP. We and others have hoped that by gaining an understanding of its mechanism of action, we might come closer to discovering the cause(s) of idiopathic Parkinson’s disease. Indeed, we have learned some fascinating things regarding the roles of monoamine oxidase B and the dopamine transport system in mediating the actions of MPTP. It is clear that the MPTP-treated mouse is a good model for Parkinson’s disease. As such, it may help to define the role of dopamine deficiency in the pathophysiology of Parkinson’s disease as well as provide a model in which potential anti-Parkinsonian therapeutic agents can be tested.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ballard P. A., Tetrud J. W., and Langston J. W. (1985) Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases.Neurology 5, 949–956.Google Scholar
  2. Bankiewicz K. S., Oldfield, E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., and Kopin I. J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Life Sci. 39, 7–16.PubMedCrossRefGoogle Scholar
  3. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., and Kopin I. J. (1983) A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proc. Natl. Acad. Sci. USA 80, 4546–4550.PubMedCrossRefGoogle Scholar
  4. Burns R. S., Phillips J. M., Chiueh C. C., and Parisi J. E. (1986) The MPTP-treated monkey model of Parkinson’s disease,MPTP:A Neurotoxin Producing a Parkinsonian Syndrome (Markey S. P., Castagnoli N., Jr., Trevor A. J., and Kopin I. J., eds.), pp. 23–42, Academic, Orlando, FL.Google Scholar
  5. Calne D. B. Langston J. W., Martin W. R. W., Stoessi A. J., Ruth T. J., Adam M. J., Pate B. D., and Schulzer, M. (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease.Nature 317, 246–248.PubMedCrossRefGoogle Scholar
  6. Chiba K., Trevor A., and Castagnoli N., Jr. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.Biochem. Biophys. Res. Commun. 120, 574–578.PubMedCrossRefGoogle Scholar
  7. Chiueh C. C., Markey S. P., Burns R. S., Johannessen J. N., Pert A., and Kopin I. J. (1984) Neurochemical and behavioral effects of systemic and intranigral administration ofN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat.Eur. J. Pharmacol. 100, 189–194.PubMedCrossRefGoogle Scholar
  8. Davis G. C., Williams A. C., Markey S. P., Ebert M. H. Caine E. D., Reichert C. M., and Kopin I. J. (1979) Chronic Parkinsonian secondary to intravenous injection of meperidine analogues.Psychiatry Res. 1, 249–254.PubMedCrossRefGoogle Scholar
  9. D’Amato R. J., Lipman Z. P., and Snyder S. H. (1986) Selectivity of the Parkinsonian neurotoxin MPTP: Toxic metabolite MPP+ binds to neuromelanin.Science 231, 987–989.PubMedCrossRefGoogle Scholar
  10. Donnan G. A., Kaczmarczyk S. J., McKenzie J. S., Rowe P. J., Kalnins R. M., and Mendelsohn F. A. O. (1987) Regional and temporal effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine uptake sites in mouse brain.J. Neuro. Sci. 81, 261–271.CrossRefGoogle Scholar
  11. Forno L. S., Langston J. W., DeLanney L. E., Irwin I., and Ricaurte G. A. (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.Ann. Neurol. 20, 449–455.PubMedCrossRefGoogle Scholar
  12. Forno L. S., Langston J. W., DeLanney L. E., and Irwin I. (1988) An electron microscopic study of MPTP-induced inclusion bodies in an old monkey.Brain Res. 448, 150–157.PubMedCrossRefGoogle Scholar
  13. Fuller R. W. and Hemrick-Luecke S. K. (1985) Mechanism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice.Prog. Neuro-Psychopharmacol. Biol. Psychiat. 9, 687–690.CrossRefGoogle Scholar
  14. German D. C., Dubach M., Askari S., Speciale S. G., and Bowden D. M. (1988) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca Fascicularis: which midbrain dopaminergic neurons are lost?Neuroscience 24, 161–174.PubMedCrossRefGoogle Scholar
  15. Gibb W. R. G., Lees A. J., Jenner P., and Marsden C. D. (1986) Effects of MPTP in the midbrain of the marmoset,MPTP:A Neurotoxin Producing a Parkinsonian Syndrome (Markey S. P., Castagnoli N., Jr., Trevor A. J., and Kopin I. J., eds.), pp. 607–614, Academic, Orlando, FL.Google Scholar
  16. Gupta M., Felten D. L., and Gash D. M. (1984) MPTP alters central catecholamine neurons in addition to the nigrostriatal system.J. Neurochem. 44, 117–127.Google Scholar
  17. Gupta M., Gupta B. K., Bruemmer V., Sladek J. R., and Felten D. L. (1986) Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults.Neurosci. Lett. 70, 326–331.PubMedCrossRefGoogle Scholar
  18. Hadjiconstantinou M., Cavalla D., Anthoupoulou E., Laird H. E., and Neff N. H. (1985)N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine increases acetylcholine and decreases dopamine in mouse striatum: Both responses are blocked by anticholinergic drugs.J. Neurochem. 45, 1957–1959.PubMedCrossRefGoogle Scholar
  19. Heikkila R. E. (1985) Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from diffent sources.Eur. J. Pharmacol. 117, 131–133.PubMedCrossRefGoogle Scholar
  20. Heikkila R. E., Hess A., and Duvoisin R. C. (1984a) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice.Science 224, 1451–1453.PubMedCrossRefGoogle Scholar
  21. Heikkila R. E., Manzino L., Cabbat F. S., and Duvoisin R. C. (1984b) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyls-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.Nature 311, 467–469.PubMedCrossRefGoogle Scholar
  22. Javitch J. A., D’Amato R. J., Strittmatter S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin,N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by dopamine neurons explains selective toxicity.Proc. Natl. Acad. Sci. USA 82, 2173–2177.PubMedCrossRefGoogle Scholar
  23. Jenner P., Rupniak N. M. J., Rose S., Kelly E., Kilpatrick G., Lees A., and Marsden C. D. (1984) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in the common marmoset.Neurosci. Lett. 50, 85–90.PubMedCrossRefGoogle Scholar
  24. Jonsson G., Sundstrom E., Mefford I., Olson I., Johnson S., Freedman R., and Hoffer B. (1985) Electrophysiological and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.Naunyn Schmiedeberg’s Arch. Pharmacol. 331, 1–6.CrossRefGoogle Scholar
  25. Kalaria R. N., and Harik S. I. (1987) Blood-brain barrier monoamine oxidase: Enzyme characterization of cerebral microvessels and other tissues from six mammalian species, including human.J. Neurochem. 49, 856–864.PubMedCrossRefGoogle Scholar
  26. Langston J. W., Ballard P., Tetrud J. W., and Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.Science 219, 979–980.PubMedCrossRefGoogle Scholar
  27. Langston J. W., Forno L. S., Rebert C. S., and Irwin I. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in squirrel monkey.Brain Res. 292, 390–394.PubMedCrossRefGoogle Scholar
  28. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., and Herkenham M. A. (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism.Nature 311, 464–467.PubMedCrossRefGoogle Scholar
  29. Mayer R. A., Walters A. S., and Heikkila R. E. (1986) 1-methyl-4-phenyl-1,2,3,6-tetrahydropridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity.Eur. J. Pharmacol. 120, 375–377.PubMedCrossRefGoogle Scholar
  30. Melamed E., Rosenthal J., Globus M., Cohen O., Frucht Y., and Uzzan A. (1985) Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice.Eur. J. Pharmacol. 114, 97–100.PubMedCrossRefGoogle Scholar
  31. Mitchell I. J., Cross A. J., Sambrook M. A., and Crossman A. R. (1985) Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.Neurosci. Lett. 61, 195–200.PubMedCrossRefGoogle Scholar
  32. Nicklas W. J., Vyas I., and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.Life Sci. 36, 2503–2508.PubMedCrossRefGoogle Scholar
  33. Nicklas W. J., Youngster S. K., Kindt M. V., and Heikkila R. E. (1987) MPTP, MPP+ and mitochondrial function.Life Sci. 40, 721–729.PubMedCrossRefGoogle Scholar
  34. Parisi J. E. and Burns R. S. (1986) The neuropathology of MPTP-induced Parkinsonism in man and experimental animals,MPTP:A Neurotoxin Producing a Parkinsonian Syndrome (Marke S. P., Castagnoli N., Jr., Trevor A. J., and Kopin I. J., eds), pp. 141–148, Academic, Orlando, FL.Google Scholar
  35. Pileblad E. and Carlsson A. (1985) Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain.Neuropharmacology 24, 689–692.PubMedCrossRefGoogle Scholar
  36. Ramsay R. R., Salach J. I., and Singer T. P. (1986) Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD-linked substrates by MPP+.Biochem. Biophys. Res. Commun. 134, 743–748.PubMedCrossRefGoogle Scholar
  37. Riachi N. J. and Harik S. I. (1988) Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier.Life Sci. 42, 2359–2363.PubMedCrossRefGoogle Scholar
  38. Ricaurte G. A., DeLanney L. E., Irwin I., and Langston J. W. (1987a) Older dopaminergic neurons do not recover from the effects of MPTP.Neuropharmacology 26, 97–99.PubMedCrossRefGoogle Scholar
  39. Ricaurte G. A., Irwin I., Forno L. S., DeLanney L. E., Langston E., and Langston J. W. (1987b) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.Brain Res. 403, 43–51PubMedCrossRefGoogle Scholar
  40. Sayre L. M., Arora P. K., Feke S. C., and Urbach F. L. (1986) Mechanism of induction of Parkinson’s disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminaldimethyl-blocked analogue of a postulated toxic metabolite.J. Am. Chem. Soc. 108, 2464–2466.CrossRefGoogle Scholar
  41. Schneider J. S. and Denaro F. J. (1988) Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).J. Neuropathol. Exp. Neurol. 47, 452–458.PubMedCrossRefGoogle Scholar
  42. Schneider J. S., Yuwiler A., and Markham C. H. (1986) Production of a Parkinson-like syndrome in the cat withN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry.Exptl. Neurol. 91, 293–307.CrossRefGoogle Scholar
  43. Schneider J. S., Yuwiler A., and Markham C. H. (1987) Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.Brain Res. 411, 144–150.PubMedCrossRefGoogle Scholar
  44. Sershen H., Mason M. F., Hashim A., and Lajtha A. (1985) Effect ofN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age related changes in dopamine turnover and transporter function in the mouse striatum.Eur. J. Pharmacol. 113, 135–136.PubMedCrossRefGoogle Scholar
  45. Singer T. P., Castagnoli N., Jr., Ramsay, R. R., and Trevor A. J. (1987) Biochemical events in the development of Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.J. Neurochem. 49, 1–8.PubMedCrossRefGoogle Scholar
  46. Snyder S. H. and D’Amato R. J. (1986) MPTP: A neurotoxin relevant to the pathophysiology of Parkinson’s disease.Neurology 36, 250–258.PubMedGoogle Scholar
  47. Sonsalla P. K. and Heikkila R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.Eur. J. Pharmacol. 129, 339–345.PubMedCrossRefGoogle Scholar
  48. Sonsalla P. K., Youngster S. K., Kindt M. V., and Heikkila R. E. (1987) Characteristics of 1-methyl-4-(2′-Methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.J. Pharmacol. Exp. Ther. 242. 850–857.PubMedGoogle Scholar
  49. Sundstrom E. and Jonsson G. (1985) Pharmacological intereference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse.Eur. J. Pharmacol. 110, 293–299.PubMedCrossRefGoogle Scholar
  50. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57/BL/6 mice. Comparison with three other strains of mice.Brain Res. 405, 26–38.PubMedCrossRefGoogle Scholar
  51. Switzer R. C., III (1985) Argyrophilic degeneration of substantia nigra in C57 mice due to 1-methyl-4-phenyl-1,2,5,6-tetrahyropyridine (MPTP).Neurosci. Abst. 11, 992.Google Scholar
  52. Westlund K. N., Denney R. M., Rose R. M., and Abell C. W. (1988) Localization of distinct monoamine oxidase B cell populations in human brainstem.Neuroscience 25, 439–456.PubMedCrossRefGoogle Scholar
  53. Youngster S. K., Duvoisin R. C., Hess A., Sonsalla P. K., Kindt M. V., and Heikkila R. E. (1986) 1-Methyl-4-(2′ methylphenyl)-1,2,3,6-tetrahydro-pyridine (2′CH3-MPTP), is a more potent dopaminergic neurotoxin than MPTP in mice.Eur. J. Pharmacol. 122, 283–287.PubMedCrossRefGoogle Scholar
  54. Youngster S. K., Sonsalla P. K., and Heikkila R. E. (1987) Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.J. Neurochem. 48, 929–934.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1989

Authors and Affiliations

  • Richard E. Heikkila
    • 1
  • Beth-Anne Sieber
    • 1
  • Lawrence Manzino
    • 1
  • Patricia K. Sonsalla
    • 1
  1. 1.Department of NeurologyUniversity of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical SchoolPiscataway

Personalised recommendations